How do drug developers select the right CDMO to advance their molecules to market? A global CDMO shares advice on how to form the strongest outsourcing partnerships.
In this co-sponsored webinar brought to you by Samsung Biologics and Pharma's Almanac, Daniel Buckley of Samsung Biologics presents on current dynamics in the CDMO market and key attributes that differentiate the strongest outsourcing partnerships. Watch the full webinar to gain valuable industry insights.
In this webinar, you will learn:
The critical challenges developers face that CDMOs help overcome
How to evaluate the capabilities of potential providers to determine right fit
Samsung Biologics' capabilities and unique platforms
Future trends on the horizon in the contract development space
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
Samsung Biologics is a full service CDMO focused on the development and manufacture of biologics for the improvement of global healthcare. Established in 2011, Samsung Biologics offers a full range of solutions for the biopharmaceutical industry, including cell line process and analytical method development, analytical services, and bulk cGMP manufacturing of drug substance and drug product from clinical to commercial scale. Based in Incheon, South Korea, Samsung Biologics’ four manufacturing facilities are optimized for the production of monoclonal and recombinant drug substance and drug product, and operate with strict adherence to quality assurance, quality control and global regulatory compliance standards. Samsung Biologics' Plant 4, the world's largest single biomanufacturing plant, began GMP operations in 2022.
.svg)
